C07K 14/48
Nerve growth factor [ngf]
Official title: Nerve growth factor [NGF]
C07K14/48 (Nerve growth factor [ngf]) appears on 200 US grants and 229 published applications in this corpus.
Search patents in C07K- Granted patents
- 200
- Published applications
- 229
- Assignees
- 161
- Inventors
- 506
- Latest grant
- 23 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1980 | 1 | 0 |
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 6 | 0 |
| 1993 | 8 | 0 |
| 1994 | 3 | 0 |
| 1995 | 4 | 0 |
| 1996 | 5 | 0 |
| 1997 | 11 | 0 |
| 1998 | 7 | 0 |
| 1999 | 9 | 0 |
| 2000 | 7 | 0 |
| 2001 | 8 | 2 |
| 2002 | 6 | 5 |
| 2003 | 3 | 11 |
| 2004 | 5 | 10 |
| 2005 | 3 | 0 |
| 2006 | 5 | 5 |
| 2007 | 3 | 8 |
| 2008 | 2 | 7 |
| 2009 | 2 | 7 |
| 2010 | 2 | 10 |
| 2011 | 7 | 7 |
| 2012 | 8 | 5 |
| 2013 | 5 | 8 |
| 2014 | 2 | 9 |
| 2015 | 5 | 8 |
| 2016 | 8 | 5 |
| 2017 | 8 | 7 |
| 2018 | 5 | 16 |
| 2019 | 7 | 7 |
| 2020 | 6 | 11 |
| 2021 | 8 | 18 |
| 2022 | 8 | 8 |
| 2023 | 0 | 11 |
| 2024 | 6 | 12 |
| 2025 | 7 | 24 |
| 2026 | 7 | 8 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Nerve growth factor and methods of use thereof for neurodevelopmental disabilities associated with neonatal hypoxic-ischemic encephalopathy23 Jun 2026US 12,662,519 B2Dompé Farmaceutici S.P.A.
- Recombinant AAV vectors for treating neurodegenerative disorders21 Apr 2026US 12,605,467 B2Shanghai Vitalgen Biopharma Co., Ltd.
- Anti-NGF antibody and antigen-binding fragment thereof, preparation method, and application thereof7 Apr 2026US 12,595,298 B2Xiyuan Anjian Medicine (Shanghai) Co., Ltd
- Method of prolonging the lifespan of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) using a cerebrolysin® preparation31 Mar 2026US 12,589,118 B2Ever Nuero Pharma GmbH
- Recombinant proteins and their therapeutic uses10 Mar 2026US 12,570,708 B2
- Intranasal administration of ngf for the treatment of sensorineural hearing loss8 Oct 2026US 2026/0308216 A1Dompé Farmaceutici S.P.A.
- Method of prolonging the lifespan of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (cadasil) using a cerebrolysin® preparation24 Sep 2026US 2026/0284119 A1Ever Neuro Pharma Bmbh
- Recombinant adeno-associated virus vector30 Jul 2026US 2026/0218228 A1Quethera Limited
- Recombinant aav vectors for treating neurodegenerative disorders16 Jul 2026US 2026/0199527 A1Shanghai Vitalgen Biopharma Co., Ltd.
- Nerve growth factor and methods of use thereof for neurodevelopmental disabilities associated with neonatal hypoxic-ischemic encephalopathy2 Jul 2026US 2026/0184751 A1Dompé Farmaceutici S.P.A.
Most cited
By later US patents
- Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system353US 5,082,670 AThe Regents of the University of California · 1992
- Clostridial toxin derivatives able to modify peripheral sensory afferent functions318US 5,989,545 AMicrobiological Research Authority · 1999
- AAV-mediated delivery of DNA to cells of the nervous system222US 6,180,613 B2The Rockefeller University · 2001
- Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins194US 5,977,307 AAlkermes, Inc. · 1999
- Transferrin neuropharmaceutical agent fusion protein150US 5,672,683 AAlkermes, Inc. · 1997